登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Fc gamma RIIA / CD32a >CD1-H5223

Human Fc gamma RIIA / CD32a (H167) Protein, His Tag (SPR & BLI & MALS verified)

分子别名(Synonym)

CD32a,FCGR2A,CD32,FCG2 ,FCGR2A1,IGFR2

表达区间及表达系统(Source)

Human CD32a (H167), His Tag (CD1-H5223) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1).

Predicted N-terminus: Ala 36

Request for sequence

蛋白结构(Molecular Characterization)

Online(Ala 36 - Ile 218) P12318-1

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 21.5 kDa. The protein migrates as 29-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 24 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Human CD32a (H167), His Tag (Cat. No. CD1-H5223) SDS-PAGE gel

Human CD32a (H167), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

Human CD32a (H167), His Tag (Cat. No. CD1-H5223) MALS images

The purity of Human CD32a (H167), His Tag (Cat. No. CD1-H5223) is more than 90% and the molecular weight of this protein is around 25-35 kDa verified by SEC-MALS.

Report

活性(Bioactivity)-SPR

Biotinylated Human SPR

Immobilized Human CD32a (H167), His Tag (SPR & BLI verified) (Cat. No. CD1-H5223) on CM5 Chip via anti-His antibody, can bind  Rituximab with an affinity constant of 1.45 μM as determined in a SPR assay (Biacore T200) (QC tested).

Protocol

Biotinylated Human SPR

Rituximab immobilized on CM5 Chip can bind Human CD32a (H167), His Tag (Cat. No. CD1-H5223) with an affinity constant of 0.882 μM as determined in SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

Biotinylated Human BLI

Loaded Human CD32a (H167), His Tag (SPR & BLI verified) (Cat. No. CD1-H5223) on HIS1K Biosensor, can bind Rituximab with an affinity constant of 1.30 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized. There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIM­bearing receptors may also be coexpressed and co­engaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B, and the strength of the signal is dependent on the ratio of expression of the activating and inhibitory receptors.

 

 

前沿进展

 
 
Fc gamma RIIA / CD32a靶点信息
英文全称:Low affinity immunoglobulin gamma Fc region receptor II-a
中文全称:低亲和力免疫球蛋白γFc区受体II-a
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床一期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定